Key statistics
As of last trade Ardelyx Inc (41X:DUS) traded at 5.53, -20.16% below its 52-week high of 6.92, set on Jan 23, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 5.36 |
|---|---|
| High | 5.53 |
| Low | 5.33 |
| Bid | 5.54 |
| Offer | 5.60 |
| Previous close | 5.36 |
| Average volume | 380.00 |
|---|---|
| Shares outstanding | 245.25m |
| Free float | 237.05m |
| P/E (TTM) | -- |
| Market cap | 1.61bn USD |
| EPS (TTM) | -0.2576 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 18:32 GMT.
More ▼
- Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions
- Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
- Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026
- Ardelyx Receives New Patent for Tenapanor
- First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
- Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook
- Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week
- Ardelyx to Participate at the Jefferies Global Healthcare Conference in London
- Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference
- Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
More ▼
